• Log in
Greater Manchester Medicines Management Group - GMMMG logo
  • Home
    • Homepage
    • News Summary
    • Consultations
    • Tariff Watch
  • Joint Formulary
    • BNF Chapters
    • Formulary Requests
  • RAG/DNP
    • RAG/DNP List
    • Paediatric RAG/DNP List
    • RAG Submissions
  • Shared Care
    • Approved Shared Care Protocols
  • GMMMG Guidance
    • Clinical guidance and pathways
    • Medicines and devices recommendations
    • Information leaflets for primary care prescribers
    • High cost drugs
    • Prescribing policies
    • Operational policies
    • Primary care rebate schemes
  • Meetings
    • Membership and Terms of Reference
    • Decision Summaries
    • GMMMG Meetings
    • Clinical Reference Group
    • GMMMG Process Documents
    • Subgroup Meetings Archives
Home » RAG List Items » Ocrelizumab

Ocrelizumab

NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis

GMMMG Consultations

Complete a consultation form »

GMMMG Members Area

Access members area »

Search GMMMG

Latest news

  • Consultation: GM non-medical prescriber best practice guide

    September 2023

  • Consultation: DOAC switch to edoxaban for NVAF patients

    September 2023

  • Guidance on managing GLP1 receptor agonist shortages

    September 2023

Tariff Watch

View key price changes in the drug tariff. »

Follow GMMMG on Twitter

  • Terms and Conditions
  • Contact
  • About us
  • RSS Feed